Publications by authors named "Robab Anbiaie"

2 Publications

  • Page 1 of 1

Emotional Intelligence as A Predictor of Health-Related Quality of Life in Breast Cancer Survivors.

Asia Pac J Oncol Nurs 2019 Jul-Sep;6(3):261-268

Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Objective: The objective of this study is to explore the predictive role of emotional intelligence (EI) and its elements for health-related quality of life (HRQoL) dimensions in a sample of breast cancer survivors.

Methods: This cross-sectional study was conducted in a single oncology clinic at a university hospital. A sample of breast cancer survivors ( = 180) completed three questionnaires: Short-Form Health Survey SF-36 (the RAND 36-item) with 8 dimensions; Cyberia Shrink EI Test (with five elements); and demographic Characteristics. The data were analyzed using SPSS version 20 (IBM Corporation, Armonk, NY, USA). A series of multiple linear regression models were used to analyze the data.

Results: EI was a predictor for two dimensions of HRQoL components in survivors: mental (β = 0.45, < 0.001); and physical (β = 0.27, < 0.001). However, it was a better predictor for the mental HRQoL than for physical. More specifically, several elements of EI, including self-motivation, self-awareness, and self-control, demonstrated significant variance with a medium effect for prediction of dimensions of HRQoL. "Self-motivation" (β = 0.27, < 0.001) and "self-awareness" (β = 0.29, < 0.01) together were the best predictors of the variances of survivors' "general health" ( = 28%). "Self-motivation" (β = 0.39, < 0.001), and "self-control" (β = 0.19, < 0.05), also together, were the best predictors of the variances of survivors' "emotional well-being" ( = 28%).

Conclusions: Educational intervention programs should be planned by concentrating on special elements of EI, including self-motivation, self-awareness and self-control, to improve HRQoL dimensions in breast cancer survivors.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/apjon.apjon_76_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518981PMC
July 2019

Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients.

Asian Pac J Cancer Prev 2012 ;13(12):6101-4

Science and Research Tehran Branch of Islamic Azad University, Tehran Iran.

Background: Breast cancer accounts about one million from total annual ten million new diagnosed cases of neoplasia worldwide and is the main cause of death due to cancer in women. Tamoxifen is the most popular selective estrogen receptor modulator used in anti estrogen treatments. Tamoxifen must be converted into its metabolite endoxifen for biologic effects; this conversion process is catalysed by highly polymorphic cytochrome P450 2D6 (CYP2D6). This study surveyed copy number variation of the CYP2D6 gene and its possible correlation with Tamoxifen resistance in breast cancer patients.

Methods: This case control study was performed on samples taken from 79 patients with breast cancer who used tamoxifen in Yazd and Tehran Cities, Iran. Real time reactions were conducted for 10 healthy samples using the comparative Ct (Cycles threshold) method, each pair of genes being compared and samples with ratios around 1 were taken as control samples. Proliferation reactions were done by Real-Time PCR ABI Prism 7500. All registered data were transformed into SPSS 15 program and analyzed.

Results: Efficiency of PCR for both CYP2D6 and ALB genes was 100%. From all 23 drug resistant patients 21.7% had one copy, 47.8% two copies and 30.4% had three copies. Also from all 56 drug sensitive patients, 26.8% had one copy, 51.8% two copies and 21.4% had three copies. The percentage of patients with one and two copies was similar between two groups but patients with three copies were more likely to belong to the drug resistant group more. Odd ratios for one and two copies were 0.759 and 0.853 respectively, indicating possible protective effects while that for three copies was 1.604.

Conclusions: Based on our study there is no significant link between CYP2D6 gene copy numbers and tamoxifen resistance in women with breast cancer. But more studies considering other influencing factors appear warranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.7314/apjcp.2012.13.12.6101DOI Listing
April 2016